Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CCNH | P51946 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554790 | 0.90 | RAB9A (0.50) | HDAC2HDAC1HDAC3HDAC10HDAC6 | |
| SCHEMBL13554827 | 0.90 | MAPT (0.49) | RAF1BRAF | |
| SCHEMBL13552803 | 0.90 | KCNH2 (0.47) | KCNH2HDAC2HDAC1HDAC3HDAC10 | |
| SCHEMBL13554665 | 0.89 | DGAT1 (0.42) | KCNH2HDAC2HDAC1TRPV1RAF1 | |
| SCHEMBL13554826 | 0.87 | TRPV1 (0.42) | KCNH2HDAC2HDAC1HDAC3TRPV1 | |
| SCHEMBL13552809 | 0.82 | TRPV1 (0.48) | TRPV1 | |
| SCHEMBL13554599 | 0.81 | SMN1; SMN2 (0.53) | — | |
| SCHEMBL2619322 | 0.80 | HDAC2 (0.60) | KCNH2HDAC2HDAC1HDAC3HDAC10 | |
| SCHEMBL13552812 | 0.80 | MAPT (0.54) | RAF1BRAF | |
| SCHEMBL13552801 | 0.80 | RAB9A (0.54) | HDAC2HDAC3HDAC10HDAC6CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | SHH, GLI1, SMO | KCNH2 3643/4885HDAC2 1722/4885HDAC1 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.